When combined with an alphavirus replicon particle-based vaccine encoding the TRP2 melanoma antigen, anti-GITR agonist antibody induced significantly enhanced therapeutic efficacy compared to anti–CTLA-4 mAb plus TRP2 vaccine. Here, CTLA4 is linked to melanoma.